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Simple Summary: The last World Health Organization classification of Tumours of Haematopoietic
and Lymphoid Tissues defines a new category, EBV + DLBCL, NOS, which incidence varies among
different populations. Given the oncogenic characteristics of both latent and lytic viral proteins, EBV
could replace some of the cellular pathways and/or mutations observed in non EBV-associated cases.
In addition, the virus may turn the tumor microenvironment in a tolerogenic, in order to promote
tumorigenesis, and may have also influence on survival in specific populations. The analysis of EBV
pathogenesis in DLBCL may exhibit new potential targets for DLBCL treatment.
Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin’s lymphoma
(NHL) in adults. Epstein–Barr virus (EBV) positive DLBCL of the elderly was defined by the World
Health Organization (WHO) in 2008, it was restricted only to patients older than 50 years old, and it
was attributed to immunesenescence associated with physiological aging. After the description of
EBV-associated DLBCL in children and young adults, the WHO redefined the definition, leading to
the substitution of the modifier “elderly” with “not otherwise specified” (EBV + DLBCL, NOS) in
the updated classification, and it is no more considered provisional. The incidence of EBV + DLBCL,
NOS varies around the world, in particular influenced by the percentage of EBV+ cells used as cut-off
to define a case as EBV-associated. EBV has effect on the genetic composition of tumor cells, on
survival, and at the recruitment of immune cells at the microenvironment. In this review, the role of
EBV in the pathogenesis of DLBCL is discussed.
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1. Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most frequent non-Hodgkin’s lym-
phoma (NHL) in adults. The World Health Organization (WHO) in 2008 defined provi-
sional entity of DLBCL, based numerous studies performed in Asian population, that was
named “Epstein–Barr virus (EBV) positive DLBCL of the elderly”. These tumors occur in
apparently immunocompetent patients usually older than 50 years old and have a worse
prognosis than EBV tumors, and they were attributed to immunesenescence associated with
physiological aging [1]. Afterward, several groups studied EBV-association with DLBCL
in children and young adults, demonstrating that EBV positivity is also detected in those
age groups, that exhibited a larger morphological spectrum, along with a better survival.
In consequence, the term “elderly” was substituted in the 2017 classification, with “not
otherwise specified” (EBV + DLBCL, NOS), and it is no more considered provisional [2,3].
EBV-positive DLBCL, NOS, is an EBV-positive clonal B-cell lymphoid proliferation. The
NOS designation excludes other more specific types of EBV-positive lymphoma. Therefore,
routine EBV testing is required for all DLBCL, NOS cases to define this specific entity [2].
In this review, EBV involvement in DLBCL pathogenesis will be discussed.
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2. EBV Association with Lymphoma
Cancers that are attributable to infections have a greater incidence than any individual
type of cancer worldwide. The International Agency for Research on Cancer (IARC)
classified 11 pathogens as carcinogenic agents in humans, which include EBV [4,5]. EBV is
a gammaherpesvirus with striking biological properties. EBV establishes latent infection
in lymphocytes, triggering the proliferation of the latently infected cells [6] once the virus
was orally transmitted from the saliva of healthy carriers with latent persistent infection [7].
In the oropharyngeal epithelium, it enters the crypts, and passes through the epithelial
cells layer to infect resting B cells, to drive them to become a proliferating lymphoblast.
Then, as proposed by the “germinal center (GC)” model of viral infection, EBV-infected
cells become involved in the GC reaction when they enter to the GC, where the virus
downregulates the pattern of latent proteins towards to the default program [8,9]. Finally,
the virus establishes a persistence in memory B cells for life, in which it could express
alternatively the EBNA1 only program, or the latency program, with no viral proteins
expressed at all [9]. Occasionally, due to the reactivation from latency into virus lytic cycle
by several mechanisms, the virus replicates at the secondary foci at oropharyngeal sites,
in order to ultimately disseminate to other hosts [10]. The successive downregulation of
almost all EBV-latent proteins enables the infected cells to escape the immune recognition,
thus becoming almost invisible to the immune system during viral persistence for lifetime.
Furthermore, EBV is also able to replicate productively in epithelial cells, and besides,
it has the ability to infect T cells and natural killer (NK) cells [7]. The infection on T
cells is mediated by the viral glycoprotein gp350 and the CD21 receptor on T cells [11].
Furthermore, it was suggested that EBV type 2 exploits the T cell compartment to persist,
and, in humanized mouse model infected by EBV2, both T cells and B cells are infected,
and most animals develop a B cell lymphoma resembling DLBCL [12].
Both innate and adaptative immune responses are responsible for the viral immune
control in the immunocompetent host during persistence and occasional reactivations, as
a result of a delicate balance between infection and host immune response. NK cells are
involved in the control of the first steps of primary infection, by the restriction of lytic
infection, especially in children [13,14]. Both CD4 and CD8 T cell responses are implicated
in the control of primary and the persistent cycles of infection. Primary EBV infection
triggers in the blood large expansion of virus-specific CD8+ T cells, along with modest
expansion of virus-specific CD4+ T cells. In persistent infection, in healthy carriers, CD8+
T cell population against lytic and latent EBV epitopes may constitute up to 2% and 0.5%
of the CD8+ T cell population, respectively, while EBV-specific memory CD4+ T cells are
stimulated to produce multiple cytokines following antigen challenge [15].
The low incidence of these EBV-associated lymphomas in immunocompetent indi-
viduals highlights the key role of the immune system mounted by carriers against EBV
primary and persistent infection, in order to control and maintain the virus in the reservoir
of persistent latent infection. However, since it induces the permanent proliferation of the
infected lines in vitro, driven by the combined action of Epstein–Barr virus nuclear antigens
(EBNAs) and latent membrane proteins (LMPs) [16], EBV could be associated with several
lymphomas, especially if the balance between viral persistence and the immune response
is disrupted. EBV is causally associated with B and T/NK lymphoproliferative diseases
(LPD), and also with distinct tumors, namely: Burkitt lymphoma (BL), diffuse large B cell
lymphoma (DLBCL), Hodgkin lymphoma (HL), plasmablastic lymphoma, (PBL), T/NK
cell lymphomas, gastric carcinoma, nasopharyngeal carcinoma (NPC), leiomyosarcoma,
and primary effusion lymphoma (PEL), in which both EBV and KSHV are present [17].
3. Epidemiology of EBV + DLBCL in Different Populations
EBV + DLBCL was initially described in Asian populations, restricted to patients
older than 50 years old, reason why it was initially defined as a provisional entity, EBV
+ DLBCL of the elderly, by the WHO in 2008 [1]. Oyama et al. described EBV presence
in 22 patients with large cell lymphoma without predisposing immunodeficiency, which
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expressed the EBV-encoded RNA (EBER) in the nuclei of the malignant cells [18]. Afterward,
characterization of the EBV presence in DLBCL cases from Japan ranged from 3 to 14%;
even though most studies included patients older than 50 years old, a few patients were
younger [19–24]. When this study was extended to DLBCL in other Asiatic populations, the
prevalence of EBV + DLBCL was 4–14% [25–29]. On the other hand, in Western countries,
EBV association with DLBCL is restricted to less than 5% of cases [30–33]. Of note, in
Latin America, Mexico, Peru, and Argentina, all developing populations where EBV infects
young children mostly without symptoms [5], the prevalence of EBV + DLBCL in adults
achieved 7% [32], 15% [34,35], and 9% [36], respectively. Furthermore, EBV was also
associated to immunocompetent pediatric DLBCL patients from Argentina and Iraq [37,38]
(Table 1).
Table 1. EBV + DLBCL in different populations.






Type EBV Effect on Survival
Oyama et al., 2007 [18] 5.5% >50% Japan II/III 60% (17 months) #
Oyama et al., 2007 [19] 14% >50% Japan II/III EBV + inferior survival
Park et al., 2007 [20] 9% >20% Korea NA EBV + inferior survival
Sato et al., 2014 [22] 6.9% >30% Japan II/III EBV + inferior survival
Wada et al., 2011 [23] 5.2% >20% Japan NA No difference
Yamauchi et al., 2007 [24] 2% NS Japan NA NS
Pan et al., 2013 [25] 3.8% >50% China NA EBV + inferior survival
Lu et al., 2015 [27] 14% >20% China NA EBV + inferior survival
Chang et al., 2014 [28] 4.5% >10% Taiwan II/III EBV + inferiorsurvival (trend)
Hong et al., 2015 [29] 8.4% >20% Korea NA EBV + inferior survival
Gibson et al., 2009 [30] 5.3% 80% USA NA NS
Hoeller et al., 2010 [31] 3.1% >10% Switzerland,Italy, Austria II/III EBV + inferior survival
Hofscheier et al., 2011 [32] 8.1% 90% Mexico II/III NS
Tracy et al., 2018 [33] 4.4% >30% USA NA No difference
Beltran et al., 2011 [34] 19.6% >20% Peru 40% (3 years) #
Cohen et al., 2014 [36] and 2017 [39] 9.3% >20% Argentina II/III EBV + inferior survival
Uccini et al., 2015 [38] 54% NS Irak II 2/6 CR #
Ohashi et al., 2017 [40] 4.5% >80% Japan NA EBV + inferior survival
Ok et al., 2014 [41] 4% >10% USA NA No difference
Lu et al., 2014 [42] 16.9% >20% Taiwan NA No difference
Ahn et al., 2013 [43] 8.1% >50% Korea NA EBV + inferior survival
Beltran et al., 2018 [44] 28% >20% Peru NA 54% (5 years) #
Abbreviations: NS, not specified. NA, not assessed. # Survival evaluated only in EBV + cases.
The differences in EBV prevalence in DLBCL among different populations might be
associated to the epidemiology of EBV primary infection. In the context of underdeveloped
populations, the first contact with EBV usually happens in the first decade of life and results
in an asymptomatic infection, while in developed ones, it occurs mainly in adolescents
or young adults, and it is symptomatic in about half of the cases, known as infectious
mononucleosis (IM) [6]. Several factors are associated with the early acquisition of primary
EBV infection, such as geographic region, race/ethnicity, and socioeconomic status [45].
However, this difference could be linked to the percentage of EBV+ cells used as a cut off
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(Table 1) (Figure 1). Even though the WHO revision in 2017 proposed that, with EBER
in situ hybridization, more than 80% of the atypical cells may be positive to consider a
DLBCL as EBV-associated [3], several studies suggested that EBV could be involved in
lymphomagenesis process in cases below this cut off. For instance, Oyama et al. applied
a cut off value of more than 50% EBERs+ cells [18], whereas Kuze et al. adopted the
criteria of almost all tumor cells with positive signals as EBV + DLBCL [21]. In addition,
Montes-Moreno et al. described a 10% cut off in their elderly DLBCL series [46], and Beltran
et al. in young immunocompetent individuals from Perú [35]. Wada et al. extensively
discussed the need for a uniform criterion for EBV positivity, either >20%, >50%, or almost
all tumor cells, given that, in their series from Japan, when the cut off was >20% or
>50%, the EBV-associated DLBCL cases were 3.3% or 1.0%, respectively, but they actually
adopted the 20% of EBERs+ cells as cut off [23]. In line with this, Park et al. [20] and Hong
et al. [29] referred >20% of tumor cells with positive signals by in EBERs ISH to define
EBV + DLBCL in their series. In order to further explore EBV characteristics to define
this cut off, Cohen et al. observed that cases above 20% of EBERs+ cells mostly displayed
latency II and III patterns, while all the cases below expressed latency I antigens [36,37],
suggesting that oncogenic latent viral proteins could also be involved in the pathogenesis of
EBV + DLBCL. Moreover, a role in the pathogenesis was also attributed to EBV+ bystander
cells, given that EBV + DLBCL patients and EBV − DLBCL patients with EBV+ bystander
cells tended to have high and high-intermediate International Prognostic Index scores
and poorer prognosis than EBV − DLBCL patients without EBV+ bystander cells [40]. In
addition, traces of EBV infection were detectable by high-sensitivity methods in several
EBV-associated lymphomas such as DLBCL, suggesting a “hit-and-run” mechanism [47].
Therefore, EBV may be involved in the pathogenesis of lymphoma more widely than
recognized so far.
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a pattern, characterized by the expression of EBNA1 and LMP1 and LMP2 antigens, iden-
tified as latency II [49], while BL displays latency I pattern, that predominantly expresses 
EBNA1 [48] (Table 2). In all latency types, infected cells express two EBV-encoded small 
RNAs, known as EBER-1, and EBER-2 [48]. The latent viral antigens EBNA3A, EBNA3C, 
EBNA2, EBNALP, and LMP1 were established to be essential for efficient B-cell transfor-
mation [50], while the remaining latent antigens, as well as noncoding RNAs have an in-
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Figure 1. EBER positive staining at the nucleus of (A) <1 t or cells and (B) 90% of tumor cells. Magnification 100×.
4. EBV Latent and Lytic Antigen Expression
EBV-associated lymphomas show a differential expression pattern of latent genes,
which represent the pathological counterpart of EBV latent gene expression proposed by
the “germinal center” model of infection. For instance, EBV-associated posttransplant
lymphoproliferative disorders (PTLDs) usually express all the latent genes, known as the
latency III program, that encode six nuclear (EBNA1, -2, -3A, -3B, -3C, and -LP) and three
membrane (LMP1, -2A, and -2B) antigens, along with untranslated RNAs [48]. H express
a pattern, characterized by the expressio of EBNA1 and LMP1 and LMP2 antigens, identi-
fied as latency II [49], while BL displays latency I pattern, that predominantly expresses
EBNA1 [48] (Table 2). In all latency types, infected cells express two EBV-encoded small
RNAs, known as EBER-1, and EBER-2 [48]. The latent viral antigens EBNA3A, EBNA3C,
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EBNA2, EBNALP, and LMP1 were established to be essential for efficient B-cell transfor-
mation [50], while the remaining latent antigens, as well as noncoding RNAs have an
influence on B-cell transformation and maintenance of B-cell outgrowth [48]. Furthermore,
several studies also demonstrated the importance of the lytic cycle, or at least its initiation,
in supporting EBV-driven malignancies [51].
Table 2. EBV latency patterns in viral associated malignancies.
EBV-Associated Neoplasia Latency Type Viral Antigen Expression
Burkitt lymphoma (sporadic and endemic) I EBERs,miRNAs, EBNA1
Gastric carcinoma I EBERs,miRNAs, EBNA1
NK/T cell lymphoma I EBERs,miRNAs, EBNA1
Plasmablastic lymphoma I EBERs,miRNAs, EBNA1
Primary effusion lymphoma I EBERs,miRNAs, EBNA1
Hodgkin lymphoma II EBERs,miRNAs, EBNA1, LMP1, 2A, 2B
Nasopharyngeal carcinoma II EBERs,miRNAs, EBNA1, LMP1, 2A, 2B
Diffuse large B cell lymphoma II EBERs,miRNAs, EBNA1, LMP1, 2A, 2B
Diffuse large B cell lymphoma III EBERs,miRNAs, EBNA1, LMP1, 2A, 2B, EBNA2, EBNA3A,3B, 3C, LP
Postransplant lymphoproliferative disorder III EBERs,miRNAs, EBNA1, LMP1, 2A, 2B, EBNA2, EBNA3A,3B, 3C, LP
Abbreviations: EBERs, Epstein Barr encoded RNAs; miRNA, microRNAs; EBNA1, Epstein Barr Nuclear Antigen 1; EBNA2, Epstein Barr
Nuclear Antigen 2; EBNA3, Epstein Barr Nuclear Antigen 3; LMP1, latent membrane protein 1; LMP2, latent membrane protein 2.
The growth-transforming capacity of EBV proteins, in particular the latent ones, drives
the EBV-infected cells in proliferation by activating several pathways [17]. LMP1, the most
important viral oncogenic protein, activates major cellular pathways to trigger B-cell
transformation in vitro, including the ERK, JNK, and p38 signaling pathways, and the NF-
kB pathway, whereas it also induces the expression of several cellular factors comprising
CD21, CD40, ICAM1, LFA1, and other adhesion factors [16]. In addition, the remaining
latent proteins also contribute to a greater or lesser extent to EBV-mediated tumorigenesis.
LMP2A acts as a normal B cell receptor (BCR), providing a tonic survival signaling to B
cells, which, even in the absence of a BCR, are able to drive GC formation [8,52]. When
coexpressed with LMP1 at the GC, they modulate each other. In fact, LMP2A alone would
ensure that the cells form GCs, then LMP1 and LMP2A together provide the requisite
survival signals, to end with the LMP1 expression alone, that ensures exit from the GC and
terminal differentiation [8]. On the other hand, EBNA2 induces the transcription of the
cellular oncogene MYC, which induce a proliferative state along with apoptosis. However,
the cooperation of EBNA3A and EBNA3C rescue infected cells from apoptosis via the
downregulation of the proapoptotic BIM and p16INK4a proteins [51]. Viral EBNAs also
target a wide range of cellular processes from genome maintenance, gene expression, cell
cycle regulation, and tumor suppression, to contribute to the EBV mediated B-lymphocyte
transformation. EBNA1 specifically ensures the segregation of viral genome to daughter
cells during mitosis of EBV-infected cells [16]. The non-coding RNAs expressed by EBV
include, besides the two EBERs, 44 miRNAs, which has an impact on several signaling
pathways essential for cell survival to optimize EBV-mediated B cell transformation [51].
Given the fact that EBV + DLBCL was initially described in elderly patients, and im-
munosenescence was proposed as a pathogenic factor for deregulation of EBV-transforming
proteins, the expression of all viral proteins, the latency III pattern, was presumed. How-
ever, in the first provisional entity in 2008 and in the revised version in 2017, both latency
II and latency III profile were observed. In fact, EBNA2 and EBNA3A expression, which
defines latency III pattern, was demonstrated in elderly cases [18,19,21,31,53], and in
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the context of immunosuppression [33]. Nevertheless, both latency II and III patterns
were described in young immunocompetent DLBCL patients [36,54], and in children with
EBV + DLBCL, NOS [37,38]. Even though latent viral antigens were associated with several
degrees of transforming capacity, lytic cycle, or at least its first steps, could be involved in
lymphomagenesis. In fact, it was proposed that lytic replication in EBV-associated malig-
nancies is not directly linked to EBV particle production, but also has influence on the tumor
microenvironment that promotes tumorigenesis [53]. In EBV + DLBCL, immediate-early
BZLF1, early BHRF1 and BMRF1, late BLLF1 lytic viral genes expression was detected, and
their expression was correlated with IL10 and IFNγ expression, revealing a link between
viral lytic cycle and EBV + DLBCL pathogenesis [55].
5. Cellular Gene Expression
Two subtypes of EBV + DLBCL, NOS were identified. The most frequent polymor-
phous subtype, in which medium neoplastic cells with Hodgkin/Reed–Sternberg-like cells
are distributed in a reactive background with histiocytes, lymphocytes, and plasma cells. In
contrast, the monomorphic subtype is characterized by large neoplastic cells with centrob-
lastic or immunoblastic morphology, without a polymorphous inflammatory background.
Large areas of geographical necrosis or apoptosis can be observed in both subtypes [56,57].
In EBV + DLBCL, NOS the neoplastic cells are usually positive for the B-cell antigens CD19,
CD20, CD22, CD79a, and PAX5 [3]. In addition, CD30 is frequently positive and CD15 is
coexpressed in a few cases [3]. In EBV + DLBCL, NOS, the activation of the JAK/STAT
and NF-kB pathways, which triggers the expression of phosphorylated STAT3 and NF-kB,
are more frequent in comparison with EBV-negative DLBCL [41,56]. Approximately 60%
of cases display clonal rearrangement of the immunoglobulin gene [41], and clonality
assessment has been proved to be helpful for discriminating polymorphous cases from
reactive hyperplasia [2,3].
Most B cell non-Hodgkin lymphomas (B-NHLs) are derived from GC B cells, includ-
ing follicular lymphoma, BL and DLBCL, which together account for 80% of B-NHLs, as
revealed by the presence of somatically mutated immunoglobulin genes in their genomes.
DLBCL represents arrested B cells induced by different transformation events that occur
at various stages of the GC transit. The cell-of-origin (COO) classification revealed that
the germinal center (GC)-like subtype of DLBCL look like light zone B cells, whereas
activated B cell (ABC)-like DLBCL originate from GC cells arrested during the early stages
of post-GC plasma cell differentiation [58]. Furthermore, GC DLBCL was shown to be
related with normal GC B cells that are in the light zone early or intermediate stages, while
most ABC-DLBCL may originate from cells that are not yet committed to plasmablastic
differentiation [59]. The COO classification is associated with distinct clinical outcomes,
with GCB cases being, usually, less aggressive than ABC cases [60]. The COO classification
in DLBCL was assessed by two different approaches. In one hand, GC and ABC subtypes
were defined by gene expression analysis (GEP), even in formalin fixed paraffin embedded
samples, using different technologies such as Lymph2X, which identified patient groups
with significantly different outcomes after R-CHOP [61], particularly in the presence of
BCL2 alterations [62]. When GEP analysis is not available in clinical practice, the immuno-
histochemistry (IHC) based Hans algorithm [63] can be used as a surrogate marker, since
it displays an overall concordance of 72% with GEP [64]. In EBV + DLBCL characterized
with Hans immunohistochemical markers, ABC-associated proteins IRF4, MUM1, are
typically positive, whereas GC markers CD10 and BCL6 are usually negative. In line with
this, GEP analysis confirmed ABC prevalence in EBV-associated cases [41,65,66], even in
children [38]. However, in several populations, no significant difference was observed in
EBV + DLBCL between the GCB and ABC subtypes [67,68]. The predominance of ABC may
be originated by the LMP1 latent viral protein, expressed in both latency II and III patterns,
which mimics a CD40 receptor constitutively activated, that in turn induces the activation
of the NF-kB /IRF4 pathway [46], thus leading to BCL6 downregulation [69]. Furthermore,
gene expression profile (GEP) in EBV + DLBCL revealed that the JAK-STAT and NF-kB
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pathways were enriched in EBV + DLBCL, and this finding was confirmed in vitro in cell
lines, and also in patients by immunohistochemical staining [39]. In addition, GEP by
microarray analysis proved 148 differentially expressed genes, including 97 upregulated
and 51 downregulated genes in EBV + DLBCL compared with EBV − DLBCL [70].
6. Genetic Alterations
Advances in molecular biology led to understand the key oncogenic pathways in-
volved in the biological diversity of DLBCL. Next-generation sequencing (NGS) technolo-
gies identified unique molecular targets that may be exploited for therapy [71]. Genetic
alterations in DLBCL have been extensively reviewed, including the differences in GC
and ABC subtypes ([71–73] and references herein). The EBV-related transforming mech-
anisms may replace, or at least complement, the genetic alterations involved in DLBCL
development, and studies comparing EBV+ and EBV− cases were performed to enlighten
the role of EBV.
Contribution of EBV to DLBCL pathogenesis was proven to be marked regarding
chromatin remodeling MYD88 and/or CD79B genes mutations, given that their presence
is almost mutually exclusive with EBV infection, suggesting that they could represent
distinct DLBCL subgroups with different oncogenic drivers [74]. In addition, CARD11 and
EZH2 missense mutations were described in a few elderly patients with EBV + DLBCL [75].
In line with this, in a large study of EBV-related lymphoma, specifically EBV + DLBCL
cases were characterized by frequent TET2 and DNMT3A mutations and the paucity of
MYD88, CD79B, CDKN2A, and FAS alterations [76]. Zhou et al. analyzed 9 EBV+ and
6 EBV − DLBCL cases by NGS, and they reported MYC, RHOA, PIM1, MEF2B, MYD88,
and CD79B mutations in about 25% of EBV + DLBCL, compared with KMT2D, CREBBP,
PIM1, TNFAIP3, and BCL2 mutations observed in 35–65% of EBV − DLBCL cases [77]. In
a series of 11 EBV + DLBCL cases, Liu et al., described mutations in exonic regions ranging
from 3.49% ± 22.68%, identifying 57 selected distinct candidate variants, and confirmed
that the 10 most frequent mutations were in PRSS3, MUC3A, MUC16, MUC19, RLIM,
HERC2, BCAR3, PRSS1, RPA1, and AMD1 [78].
Concerning rearrangements and copy number alterations (CNA), fewer MYC, BCL2,
and BCL6 rearrangements were observed in EBV + DLBCL [74,75], reinforcing the role
of EBV as the alternative pathway to trigger DLBCL pathogenesis. Furthermore, fewer
genomic alterations were described in a series of EBV + DLBCL compared with those
observed in EBV − DLBCL cases, being the most frequent CNAs (copy number alterations)
(>30%) in EBV + DLBCLs losses at 6q27, 7q11.2, and 7q36.2–36.3; and gains at 1q23.2–23.3,
1q23.3, 1q32.1, 5p15.3, 8q22.3, 8q24.1–24.2, and 9p24.1 [71]. Additionally, genome-wide
high-resolution screening for CNAs in a series of 24 EBV + DLBCL samples revealed
copy number gains, 1p36.33, 2p11.2, 6p22.1, 6p22.2, 6q14.3, 9p13.3, 10p11.22, 14q32.33,
17p13.1, 20p11.22, and 20p13, whereas cytogenetic losses involved regions 1p36.33, 2p11.2,
2q37.3, 8q24.3, 10q26.3, 15q11.1–q11.2, 16p11.2, 20q13.33, and 21q11.2 [75]. In contrast,
the EBV presence could be associated with the upregulation of specific genes involved
in immune evasion, such as PDL1 and PDL2. In fact, EBV presence in tumor cells was
proposed as an alternative mechanism for PDL1 induction, given the fact that 9p24.1
amplification, the gene that encodes for PDL1, and EBV infection were proved to be
mutually exclusive in a series of Hodgkin lymphoma [79]. In line with this, high fre-
quency of PDL1/PDL2-involving genetic aberrations was observed in EBV-associated
lymphomas, including extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia,
systemic EBV-positive T-cell lymphoproliferative disorder, peripheral T-cell lymphoma,
not otherwise specified, and EBV + DLBCL [76,80]. Moreover, it was suggested that the
upregulation of PDL2 on 9p24.1 may induce immune evasion, and it was associated with
poor prognosis in EBV + DLBCL [70]. The amplification of PDL1 could be involved in the
increased expression of PDL1, detected by immunohistochemistry (IHC), in tumor cells in
EBV + DLBCL, which was also proved to be associated with prognosis [54,81–83]. In fact, it
was demonstrated that EBV − LMP1 increases PDL1 promoter and enhancer activity [84].
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7. Microenvironment Composition
EBV can induce a highly variable composition of the tumor microenvironment (TME),
depending on the EBV-associated tumors. The most widely studied is EBV + Hodgkin
lymphoma (HL), where TME plays a key role. Even though EBV + tumor cells are not as
immunogenic as lytically infected ones, they are capable of eliciting EBV− specific immune
responses. In fact, it has been demonstrated that EBV presence elicits a higher number of
infiltrating CD4+ T cells, in particular Treg cells that secrete IL10, and activated cytotoxic
CD8+ T cells and NK cells [85]. Besides, in HL, significantly higher numbers of tumor
associated macrophages were observed in EBV+ HL as compared to EBV-cases [85,86].
Furthermore, immune scape in EBV-associated cancers can be triggered by overexpression
of PDL1/PDL2 and CTLA-4, which induce T cell exhaustion [79,87–89].
Regarding EBV-associated DLBCL, strong PDL1 expression in tumor cells of patients
with EBV+DLBCL was observed, suggesting a mechanism of induction of immune tol-
erance [83]. Nevertheless, given that PDL1 can be also expressed in immune cells at the
microenvironment, PDL1 expression was also demonstrated in the TME of EBV + DLBCL
cases, as a mechanism to strengthen immune exhaustion. Kiyasu et al. discriminated PDL1
expression in tumor cells and at the microenvironment, and described that PDL1 + cells
at the TME was significantly associated with EBV positivity, whereas, unexpectedly, the
number of the PD1+ tumor infiltrating lymphocytes, the ligand of PDL1, was not related
to EBV presence [90]. In line with this, in young patients EBV + large cell lymphomas
displayed dysregulation of immune checkpoints, IDO, and PD1/PDL1 axis, promoting a
tolerogenic immune environment [54]. PDL1 expression in nonmalignant cells comprised
mainly tumor-infiltrating macrophages, in EBV + DLBCL, and in other lymphomas, by dou-
ble immunostaining for CD68 or PAX5 and PDL1 [91]. PDL1 expression in macrophages
could be induced as a response to IFNγ, an antitumoral and antiviral cytokine [84]. Fur-
thermore, in patients with EBV+ posttransplant lymphoproliferative disorders (PTLD),
latency II or III profiles were strongly associated with PDL1 expression in tumor associated
macrophages (TAMs) compared with EBV− cases, and also with cases expressing latency
I [92], suggesting that latency II and III viral genes, such as LMP1, could be involved in
PDL1 upregulation. Increased PDL1 expression was also observed in EBV + DLBCL cell
lines, which increased the expression of PD1 on T cells in vitro, with the subsequent de-
creased on T cell proliferation. The intratumoral PD1+ T cells were mostly exhausted CD8+
memory T cells that produced more IL-2, IFN-γ, IL-10, and TNF-α after PD1 blockade [93].
The immune regulatory environment observed in EBV + DLBCL also involves in-
creased gene expression of immunosuppressive cytokine IL10 [68], which could be trig-
gered directly by LMP1 [93], and/or lytic antigens [55], or, alternatively, by the presence of
regulatory T cells that secrete IL10, as observed in EBV-associated HL, nasopharyngeal and
gastric carcinomas, and in EBV-transformed B cell lines [84,94]. However, in EBV + DLBCL
the regulatory environment coexists with the increased expression of CD8+ T-cells and
granzyme B+ cytotoxic effector cells [68], also known as “inflamed phenotype” by gene
expression analysis [72]. Nevertheless, the CD8+ T cell in the TME might not be efficient
to eliminate EBV-infected cells, since decreased numbers of central and effector memory
CD8+ T lymphocytes were found among EBV + DLBCL patients [95]. The presence of
immune tolerogenic environment in the context of EBV + DLBCL was also described by
gene expression analysis, which revealed increased expression of PDL1, PDL2, LAG3,
and TIM3 immune checkpoints and a higher protumoral CD163/CD68 “M2” macrophage
polarization pattern [96]. Therefore, even though EBV-associated tumors are frequently
characterized by an important inflammatory infiltrate, it may represent an ineffective
attempt of the host immune response to control virus-infected tumor cells [97].
The expression of EBV latent antigens, in particular latency II and III observed in
EBV + DLBCL, modulates the environmental immune response by a several mechanisms.
In EBV-transformed B lymphoblastoid cell lines that represents DLBCL, viral latency in-
creased the production of IL10, CCL22, and MIP-1α/CCL3 [98]. LMP1 also promotes B-cell
proliferation by inducing a STAT1-dependent IFN-γ secretion [99], whereas both LMP2A
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and EBERs latent antigens, and BZLF1 lytic one, enhance IL10 production [97,100–102],
highlighting the relevance of IL10 expression in B-cell transformation. Upregulation of
IL6 and IL13, triggered by viral antigens such as EBER2 and BZLF1, may also induce
the formation of niches favorable for the growth and survival of EBV-infected tumor
cells [101,103].
8. Survival
The response to combination chemotherapy seems to be lower in EBV + DLBCL than
in EBV-negative DLBCL cases. The treatment with the anti-CD20 (rituximab) in addition
to anthracycline-based chemotherapy has clearly improved survival outcomes in patients
with DLBCL in several clinical settings. In fact, the overall response with R-CHOP varies
from 50 to 89% in different series [104].
The prognosis in EBV + DLBCL differs between elderly and young patients [3]. Overall
survival was thus significantly lower in elderly EBV + DLBCLs [22,28,29,34,46,105,106],
and an age older than 70 years was independently predictive for survival in multivariate
analysis [19]. In patients younger than 50 years, EBV positivity did not markedly influence
overall or progression free survival, but there was a trend toward poorer survival in EBV-
associated cases older than 50 years. In both univariate and multivariate analysis, EBV
presence displayed an adverse impact in ABC patients with DLBCL, but it did not influence
survival in GCB cases [20,46]. Furthermore, markedly worse survival rate was noted for
DLBCL cases displaying viral latency III pattern [31], and in EBV + DLBCL patients and
EBV − DLBCL patients with EBV+ bystander cells, compared to patients without any
detectable EBV+ cells [40]. Nicolae et al. also demonstrated, in patients with large B cell
lymphoma, that younger ones achieved a significantly higher overall survival than prior
series of EBV+ elderly cases [54]. Conversely, in elderly and young groups, EBV + DLBCL
patients showed significantly worse survival than negative cases [27,69], and also no
significant differences in clinical outcomes were identified between different age groups
with EBV positive DLBCL [27,42,107].
Quite the opposite, other studies described no significant impact of EBV on survival
in DLBCL patients [23,33,41,43,44,75,108]. Nevertheless, a few studies enlighten the effect
of EBV on prognosis in relation to other markers. Ok et al. revealed that EBV + DL-
BCL with that also express CD30 had significantly lower overall survival compared with
EBV + DLBCL without CD30 expression [41]. In addition, PDL1+ expression in a subset
of EBV + DLBCL displayed inferior clinical outcome compared with PDL1− cases, sug-
gesting a mechanism for immune evasion through PDL1 to underlie the worst outcome of
EBV + DLBCL [81,82]. Furthermore, upregulation of PDL2 on 9p24.1 also triggers immune
evasion, and was proved to be associated with poor prognosis in EBV + DLBCL [70].
9. DLBCL Associated with Chronic Inflammation
This DLBCL is a lymphoid neoplasm frequently associated with EBV infection, initially
described in Japan, and arises in the setting of longstanding chronic inflammatory process
such as chronic osteomyelitis, pyothorax, metallic implant, or chronic skin ulcers [2,44]. Fur-
thermore, it was also described in ileal neobladder, and related to breast implants [109–111].
The neoplastic cells have immunoblastic, centroblastic, or less commonly anaplastic fea-
tures, with few nucleoli and limited to moderate amounts of cytoplasm. The proliferation
rate achieves 80–100% [112]. Most lymphoma cells express CD20 and CD79a, but a propor-
tion of cases could show plasmacytic differentiation, with a loss of CD70a and/or CD20,
accompanied by the expression IRF4/MUM1 and CD138 markers. The lymphoma cells
exhibit an activated B-cell phenotype [2]. DLBCL associated with chronic inflammation
usually have a complex karyotype, with abundant numerical and structural abnormalities.
MYC amplification is quite frequent and TP53 mutations are observed in approximately
70% of cases. The immunoglobulin genes show clonal rearrangements and evidence of
somatic hypermutation [2,112]. NGS in a series of chronic inflammation DLBCL associated
with breast implant described mutations in genes known to be recurrently mutated in DL-
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BCL, such as CREBBP, GNA13, TET2, IRF4, STAT3, and SOCS1 [110]. Latency III program
is prevalent, since viral oncogenic antigens EBERs, LMP1, and EBNA-2 are positive in most
cases, which may be related to the pathogenesis of this particular DLBCL subtype [44,111].
Chronic inflammation at the local site perhaps plays a role in the proliferation of EBV-
transformed B cells, since it allows them to escape from the host immune surveillance,
as a result of the production of immunosuppressive IL10 cytokine, and the autocrine to
paracrine growth via IL6 and IL6R [2]. Furthermore, EBV + DLBCL associated with chronic
inflammation expresses CCL17 and CCL22 chemokines that are involved in the recruitment
of CCR4-expressing regulatory T cells at the microenvironment [113]. In addition, down-
regulation of HLA class I expression, and mutations of cytotoxic T-lymphocyte epitopes in
EBNA3B, an immunodominant antigen for cytotoxic T-lymphocyte responses, could also
contribute to escape of neoplastic cells from host cytotoxic T lymphocytes [2].
Included in this category is the subtype fibrin-associated diffuse large B cell lymphoma,
which is different from DLBCL associated with chronic inflammation category, given the
fact that it does not form a discrete mass, and the clinical outcome is highly favorable [114].
10. Conclusions
In summary, EBV + DLBCL, NOS, is an aggressive lymphoma subtype associated
defined by the recent WHO classification with a different impact on prognosis, according
to population background. Its definition prompt the standardization of EBERs in situ
hybridization as a routine test in pathological samples with suspected DLBCL diagnosis.
Even though the cutoff for EBER positivity considers that more than 80% of the atypical
cells may be positive to consider a DLBCL as EBV-associated [3], several groups discuss
this definition, based on latent or lytic antigen expression [23,35–37,55], or the presence
of EBV+ bystander cells in EBV − DLBCL [40]. Specific signaling pathways, such as JAK-
STAT and NF-kB pathways are enriched in EBV + DLBCL. In contrast, MYD88 and/or
CD79B mutations, and MYC, BCL2, and BCL6 rearrangements are absent in EBV+ cases [3].
To add more, EBV + DLBCL also promotes an exhausted immune microenvironment,
by the dysregulation of immune checkpoint PD1/PDL1, LAG3, and TIM3 [54,97], the
shift to a higher pro-tumoral CD163/CD68 “M2” macrophage polarization pattern [97]
or the increase of immunosuppressive cytokine IL10 [68]. Therefore, studies are required
to explore EBV antigens expressed in DLBCL, cellular pathways activated by viral pres-
ence, or microenvironment composition, in order to identify potential targets to treat this
specific entity.
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